Drugs / SR-878
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07433335 | Apr 2026 → Feb 2028 expected | rheumatoid arthritis | SciRhom GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT06607484 | Oct 2024 → Feb 2025 | — | SciRhom GmbH | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-12 | SciRhom GmbH | Regulatory SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases. scirhom.com ↗
SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by the Austrian regulatory authorities (BASG/AGES) for its development program SR-878. |
| 2023-11-15 | SciRhom GmbH | Regulatory SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases scirhom.com ↗
The company has submitted a Clinical Trial Application for its lead candidate, SR-878, a groundbreaking antibody designed to target iRhom2 as a therapeutic strategy for numerous autoimmune disorders. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR-878 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06607484 ↗ |
| Action | Inhibit | “It inhibits a protein (iRhom2)” NCT06607484 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06607484 ↗ |